Nordic Nanovector's Betalutin® Receives Fast-track Designation from US FDA for Marginal Zone Lymphoma

Corporate Breaking News

Home : Nordic Nanovector's Betalutin® Receives Fast-track Designation from US FDA for Marginal Zone Lymphoma

Jun 29 2020	Nordic Nanovector's Betalutin® Receives Fast-track Designation from US FDA for Marginal Zone Lymphoma
OSLO, Norway, June 29, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) today announces that the US Food and Drug Administration (FDA) has granted Fast Track designation for investigating Betalutin® (177Lu lilotomab satetraxetan) for the treatment of adult patients with relapsed or...


Source:https://www.prnewswire.com:443/news-releases/nordic-nanovectors-betalutin-receives-fast-track-designation-from-us-fda-for-marginal-zone-lymphoma-301084836.html

Related News
» D-Link 5G Solutions Revolutionize Mobile Connectivity » Xinhua Silk Road: online special feature on investment in south China's Hainan Jiangdong New Area launched